## Diem Vuong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1030662/publications.pdf

Version: 2024-02-01

933447 839539 24 345 10 18 h-index citations g-index papers 25 25 25 569 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. Frontiers in Oncology, 2022, 12, 830627.	2.8	2
2	Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: Multi-center study. Physics and Imaging in Radiation Oncology, 2022, 22, 131-136.	2.9	12
3	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. Frontiers in Oncology, 2021, 11, 636672.	2.8	15
4	Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types. British Journal of Radiology, 2021, 94, 20200947.	2.2	16
5	Systematic Review on the Association of Radiomics with Tumor Biological Endpoints. Cancers, 2021, 13, 3015.	3.7	11
6	Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. EJNMMI Research, 2021, 11, 79.	2.5	11
7	Quantification of theÂspatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. Scientific Reports, 2021, 11, 20890.	3.3	3
8	Radiomics Feature Activation Maps as a New Tool for Signature Interpretability. Frontiers in Oncology, 2020, 10, 578895.	2.8	17
9	Dosimetric and geometric end-to-end accuracy of a magnetic resonance guided linear accelerator. Physics and Imaging in Radiation Oncology, 2020, 16, 109-112.	2.9	13
10	Comparison of robust to standardized CT radiomics models to predict overall survival for nonâ€small cell lung cancer patients. Medical Physics, 2020, 47, 4045-4053.	3.0	23
11	Radiomic biomarkers for head and neck squamous cell carcinoma. Strahlentherapie Und Onkologie, 2020, 196, 868-878.	2.0	28
12	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. Clinical Cancer Research, 2020, 26, 4414-4425.	7.0	70
13	FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients. EJNMMI Research, 2020, 10, 81.	2.5	27
14	PO-1571: Radiomics for prediction of metastatic melanoma patient survival after immunotherapy. Radiotherapy and Oncology, 2020, 152, S851.	0.6	0
15	Benchmarking Monte-Carlo dose calculation for MLC CyberKnife treatments. Radiation Oncology, 2019, 14, 172.	2.7	6
16	Interchangeability of radiomic features between [18F]â€≺scp>FDG PET/ <scp>CT</scp> and [18F]â€≺scp>FDG PET/ <scp>MR</scp> . Medical Physics, 2019, 46, 1677-1685.	3.0	22
17	THU0345â€TEXTURE-BASED RADIOMICS FEATURES DISCRIMINATE DIFFERENT STAGES OF EXPERIMENTAL INTERSTITIAL LUNG DISEASE., 2019, , .		0
18	Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition Journal of Clinical Oncology, 2019, 37, 9575-9575.	1.6	1

#	Article	IF	CITATIONS
19	CT radiomics and PET radiomics: ready for clinical implementation?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 355-370.	0.7	58
20	Computed-tomography-based radiomics features for staging of interstitial lung disease – transferability from experimental to human lung fibrosis - a proof-of-concept study. , 2019, , .		4
21	Independent Monte-Carlo dose calculation for MLC based CyberKnife radiotherapy. Physics in Medicine and Biology, 2018, 63, 015015.	3.0	6
22	EP-1842: Benchmarking of Monte Carlo dose calculation for MLC based CyberKnife Radiotherapy. Radiotherapy and Oncology, 2018, 127, S994-S995.	0.6	0
23	76P Robustness of radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR. Journal of Thoracic Oncology, 2018, 13, S41.	1.1	0
24	EP-1480: Patient-specific QA for CyberKnife MLC plans using Monte Carlo. Radiotherapy and Oncology, 2017, 123, S791.	0.6	0